- Home
- SXTP vs RDHL Comparison
SXTP vs RDHL Comparison
Compare SXTP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- RDHL
- Stock Information
- Founded
- SXTP 2010
- RDHL 2009
- Country
- SXTP United States
- RDHL Israel
- Employees
- SXTP N/A
- RDHL N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- RDHL Health Care
- Exchange
- SXTP Nasdaq
- RDHL Nasdaq
- Market Cap
- SXTP 3.7M
- RDHL 3.9M
- IPO Year
- SXTP 2023
- RDHL N/A
- Fundamental
- Price
- SXTP $0.98
- RDHL $1.05
- Analyst Decision
- SXTP Strong Buy
- RDHL
- Analyst Count
- SXTP 3
- RDHL 0
- Target Price
- SXTP $4.50
- RDHL N/A
- AVG Volume (30 Days)
- SXTP 61.3K
- RDHL 1.5M
- Earning Date
- SXTP 11-13-2025
- RDHL 09-05-2025
- Dividend Yield
- SXTP N/A
- RDHL N/A
- EPS Growth
- SXTP N/A
- RDHL N/A
- EPS
- SXTP N/A
- RDHL N/A
- Revenue
- SXTP $1,364,945.00
- RDHL $9,550,000.00
- Revenue This Year
- SXTP $81.41
- RDHL $381.91
- Revenue Next Year
- SXTP $83.17
- RDHL N/A
- P/E Ratio
- SXTP N/A
- RDHL N/A
- Revenue Growth
- SXTP 202.10
- RDHL 157.62
- 52 Week Low
- SXTP $0.85
- RDHL $1.01
- 52 Week High
- SXTP $12.45
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- SXTP 31.86
- RDHL 34.47
- Support Level
- SXTP $0.97
- RDHL $1.01
- Resistance Level
- SXTP $1.08
- RDHL $1.07
- Average True Range (ATR)
- SXTP 0.09
- RDHL 0.12
- MACD
- SXTP -0.02
- RDHL 0.01
- Stochastic Oscillator
- SXTP 31.55
- RDHL 8.47
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.